Raf265 derivatives are primarily investigated for their potential in cancer therapy, particularly in targeting the RAF/MEK/ERK signaling pathway, which is often dysregulated in various cancers. These compounds are designed to inhibit RAF kinases, which play a critical role in cell proliferation and survival. By blocking this pathway, Raf265 derivatives can suppress tumor growth and induce apoptosis in cancer cells. They are being explored for use in melanoma, colorectal cancer, and other malignancies where RAF mutations are prevalent. Additionally, these derivatives are studied in combination therapies to enhance efficacy and overcome drug resistance. Research is ongoing to optimize their pharmacokinetic properties and reduce off-target effects for clinical applications.